Age group | hrHPV positive | Bivalent vaccine types^{a} | Nonbivalent vaccine types^{b} | Polyvalent vaccine types^{c} | Nonpolyvalent vaccine types^{d} | ||||
---|---|---|---|---|---|---|---|---|---|
N | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |
POBASCAM | |||||||||
29–33 | 108 | 44 | 40.7 (31.4–50.6) | 77 | 71.3 (61.8–79.6) | 88 | 81.5 (72.9–88.3) | 34 | 31.4 (22.9–41.1) |
34–38 | 125 | 48 | 38.4 (29.8–47.5) | 89 | 71.2 (62.4–78.9) | 94 | 75.2 (66.7–82.5) | 45 | 36.0 (27.6–45.1) |
39–43 | 68 | 25 | 36.8 (25.4–49.3) | 47 | 69.1 (56.7–79.8) | 47 | 69.1 (56.7–79.8) | 24 | 35.3 (24.1–47.8) |
44–48 | 56 | 13 | 23.2 (13.0–36.4) | 45 | 80.4 (67.6–89.8) | 34 | 60.7 (46.8–73.5) | 24 | 42.3 (29.7–56.8) |
49–53 | 45 | 16 | 35.6 (21.9–51.2) | 30 | 66.7 (51.0–80.0) | 31 | 68.9 (53.4–81.8) | 15 | 33.3 (20.0–49.0) |
54–56 | 21 | 8 | 38.1 (18.1–61.6) | 13 | 61.9 (38.4–81.9) | 16 | 76.2 (52.8–91.8) | 5 | 23.8 (8.2–47.2) |
Total | 423 | 154 | 36.4 (31.8–41.2) | 301 | 71.1 (66.6–78.4) | 310 | 73.3 (68.8–77.4) | 147 | 34.8 (30.2–39.3) |
Linear effect: regression coefficient (SE)^{e} | −0.011 (0.014) | 0.004 (0.015) | −0.025 (0.147) | 0.014 (0.014) | |||||
Nonlinear effect: regression coefficient (SE)^{f} | 0.002 (0.002) | −0.002 (0.002) | 0.004 (0.002)^{g} | −0.003 (0.002) | |||||
NTCC | |||||||||
24–28 | 65 | 26 | 40.0 (28.0–52.9) | 47 | 72.3 (59.8–82.7) | 46 | 70.8 (58.2–81.4) | 28 | 43.1 (30.8–56.0) |
29–33 | 53 | 28 | 52.8 (38.6–66.7) | 32 | 60.4 (46.0–73.5) | 44 | 83.0 (70.2–91.9) | 15 | 28.3 (16.8–42.3) |
34–38 | 40 | 10 | 25.0 (12.7–41.2) | 23 | 80.0 (64.4–90.9) | 27 | 67.5 (50.9–81.4) | 18 | 45.0 (29.3–61.5) |
39–43 | 29 | 10 | 34.5 (17.9–54.3) | 23 | 79.3 (60.3–92.0) | 15 | 51.7 (32.5–70.6) | 15 | 51.7 (32.5–70.6) |
44–48 | 24 | 8 | 33.3 (15.6–55.3) | 18 | 75.0 (53.3–90.2) | 12 | 50 (29.1–70.9) | 12 | 50.0 (29.1–70.9) |
49–53 | 12 | 4 | 33.3 (9.9–65.1) | 10 | 83.3 (51.6–97.9) | 8 | 66.7 (34.9–90.1) | 4 | 33.3 (9.9–65.1) |
54–56 | 8 | 4 | 50.0 (15.7–84.3) | 6 | 75.0 (34.9–96.8) | 7 | 87.5 (47.3–99.7) | 3 | 37.5 (8.5–75.5) |
57–60 | 2 | 0 | 0 | 2 | 100.0 (0.16–100.0) | 1 | 50.0 (1.26–98.7) | 1 | 50.0 (1.3–98.7) |
Total | 233 | 90 | 38.6 (32.3–45.2) | 170 | 73.0 (66.8–78.6) | 160 | 68.7 (62.3–74.6) | 96 | 41.2 (34.8–47.8) |
Linear effect: regression coefficient (SE)^{e}^{,}^{g} | −0.022 (0.229) | 0.043 (0.025) | −0.046 (0.024) | 0.030 (0.021) | |||||
Nonlinear effect: regression coefficient (SE)^{f}^{,}^{g} | 0.006 (0.030)^{h} | −0.004 (0.003) | 0.010 (0.004)^{h} | −0.005 (0.003) |
↵^{a}Bivalent vaccine types includes HPV types 16 and 18.
↵^{b}Nonbivalent vaccine types includes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.
↵^{c}Polyvalent vaccine types includes HPV types 16, 18, 31, 33, 45, 52, and 58.
↵^{d}Nonpolyvalent vaccine types includes HPV types 35, 39, 51, 56, 59, and 68.
↵^{e}Regression coefficient and standard error of the linear term in logistic regression models, including age as continuous variable and adjusted for the number of infections.
↵^{f}Regression coefficient and standard error of the nonlinear (quadratic) term in logistic regression models, including age and age squared as continuous variable and adjusted for the number of infections.
↵^{g}Restricted to the same age range as POBASCAM (29–56 years). The classification in HPV types is not mutually exclusive and totals of bivalent + nonbivalent and polyvalent + nonpolyvalent types exceed the 100% as a result of multiple type infections.
↵^{h}P < 0.05.